<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996875</url>
  </required_header>
  <id_info>
    <org_study_id>CGT9486-20-201</org_study_id>
    <secondary_id>2021-001010-10</secondary_id>
    <nct_id>NCT04996875</nct_id>
  </id_info>
  <brief_title>(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis</brief_title>
  <official_title>A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cogent Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cogent Biosciences, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of&#xD;
      patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM&#xD;
      (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>There are two parts to this study. Part I will be Dose Confirmation and Part II will be Expansion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the optimal dose of CGT9486 by safety assessments and response criteria</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate according to modified IWG-MRT-ECNM response criteria</measure>
    <time_frame>18 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of CGT9486 as assessed by incidence of adverse events (AEs)</measure>
    <time_frame>18 months</time_frame>
    <description>Incidence of AEs according to CTCAE version 5.0 or higher</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mutation allele burden</measure>
    <time_frame>18 months</time_frame>
    <description>Percentage change in KIT D816V</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Tryptase</measure>
    <time_frame>18 months</time_frame>
    <description>Percentage change in Serum Tryptase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic studies</measure>
    <time_frame>18 months</time_frame>
    <description>Percentage change in plasma concentrations of CGT9486</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in histopathologic findings in blood and bone marrow</measure>
    <time_frame>18 months</time_frame>
    <description>Percentage change in mast cell infiltration in the bone marrow and percentage change in eosinophilia and monocytosis in the blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in spleen and liver volume by imaging</measure>
    <time_frame>18 months</time_frame>
    <description>Percentage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Impression of Severity (PGIS) scale</measure>
    <time_frame>18 months</time_frame>
    <description>0 -10 points (higher values represent worse symptom outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Patient Global Impression of Change (PGIC) scale</measure>
    <time_frame>18 months</time_frame>
    <description>0 - 7 points (higher values represent better symptom outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mastocytosis Quality of Life Questionnaire (MC-QoL)</measure>
    <time_frame>18 months</time_frame>
    <description>0 - 100 (higher values represent better symptom outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mastocytosis Activity Score (MAS)</measure>
    <time_frame>18 months</time_frame>
    <description>0 - 252 (higher values represent worse symptom outcomes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>18 months</time_frame>
    <description>Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>18 months</time_frame>
    <description>Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>18 Months</time_frame>
    <description>Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>18 months</time_frame>
    <description>Months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pure Pathological Response (PPR)</measure>
    <time_frame>18 months</time_frame>
    <description>Months</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Advanced Systemic Mastocytosis (AdvSM)</condition>
  <condition>SM With an Associated Hematologic Neoplasm (SM-AHN)</condition>
  <condition>Mast Cell Leukemia (MCL)</condition>
  <condition>Aggressive Systemic Mastocytosis (ASM)</condition>
  <arm_group>
    <arm_group_label>CGT9486</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CGT9486 tablets</intervention_name>
    <description>CGT9486 is supplied as tablets to be taken orally, continuously in 28-day cycles.</description>
    <arm_group_label>CGT9486</arm_group_label>
    <other_name>PLX9486</other_name>
    <other_name>bezuclastinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with 1 of the following advanced mastocytosis diagnoses by Eligibility&#xD;
             Committee:&#xD;
&#xD;
               1. Aggressive Systemic Mastocytosis (ASM)&#xD;
&#xD;
               2. Systemic Mastocytosis with an Associated Hematologic Neoplasm (SM-AHN)&#xD;
&#xD;
               3. Mast Cell Leukemia (MCL)&#xD;
&#xD;
          2. Measurable disease according to modified IWG-MRT-ECNM criteria&#xD;
&#xD;
          3. ECOG (0 to 3)&#xD;
&#xD;
          4. Have clinically acceptable local laboratory screening results (clinical chemistry,&#xD;
             hematology) within certain limits&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Persistent toxicity from previous therapy for Advanced Systemic Mastocytosis that has&#xD;
             not resolved to â‰¤ Grade 1&#xD;
&#xD;
          2. Associated hematologic neoplasm requiring immediate antineoplastic therapy&#xD;
&#xD;
          3. Clinically significant cardiac disease&#xD;
&#xD;
          4. Known positivity for the FIP1L1 PDGFRA fusion (Patients with eosinophilia without&#xD;
             detectable KIT D816V mutation must also lack the PDGFRA fusion mutation prior to&#xD;
             enrollment)&#xD;
&#xD;
          5. Seropositive for human immunodeficiency virus (HIV) 1 or 2, or positive for hepatitis&#xD;
             B surface antigen or hepatitis C virus (HCV) antibody&#xD;
&#xD;
          6. History of clinically significant bleeding event within 30 days before the first dose&#xD;
             of study drug or need for therapeutic anticoagulation on study&#xD;
&#xD;
          7. Diagnosed with or treated for malignancy other than the disease under study within the&#xD;
             prior 3 years before enrollment&#xD;
&#xD;
          8. Received any cytoreductive therapy or any investigational agent less than 14 days, and&#xD;
             for cladribine, interferon alpha, pegylated interferon, and any antibody therapy less&#xD;
             than 28 days, before screening bone marrow biopsy&#xD;
&#xD;
          9. Received hematopoietic growth factor support within 14 days before the first dose of&#xD;
             study drug&#xD;
&#xD;
         10. Received strong CYP3A4 inhibitors or inducers before the first dose of study drug&#xD;
&#xD;
         11. Need for treatment with steroids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Sachs, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cogent Biosciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hina Jolin, PharmD</last_name>
    <phone>+1 (617) 945-5576</phone>
    <email>ApexInfo@cogentbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Stanford Cancer Institute</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Galiz Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute - University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>August 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mastocytosis</keyword>
  <keyword>Systemic Mastocytosis</keyword>
  <keyword>Advanced Mastocytosis</keyword>
  <keyword>Aggressive Mastocytosis</keyword>
  <keyword>Hematologic Neoplasms</keyword>
  <keyword>Mast Cell</keyword>
  <keyword>Mast Cell Leukemia</keyword>
  <keyword>Soft Tissue Neoplasms</keyword>
  <keyword>Neoplasms by site</keyword>
  <keyword>Skin Diseases</keyword>
  <keyword>Immune Complex Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <keyword>Hypersensitivity</keyword>
  <keyword>Hematologic Diseases</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Myeloid Leukemia</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>SM with Associated Hematologic Neoplasm</keyword>
  <keyword>AdvSM</keyword>
  <keyword>ASM</keyword>
  <keyword>SM-AHN</keyword>
  <keyword>MCL</keyword>
  <keyword>Neoplasm</keyword>
  <keyword>D816V</keyword>
  <keyword>KIT D816V</keyword>
  <keyword>AML</keyword>
  <keyword>bezuclastinib</keyword>
  <keyword>CGT9486</keyword>
  <keyword>CGT</keyword>
  <keyword>PLX</keyword>
  <keyword>Connective Tissue Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Mastocytosis</mesh_term>
    <mesh_term>Mastocytosis, Systemic</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Mast-Cell</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

